David Mendoza, MD
Urology · Parkersburg, WVNPI 1255374856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Astellas Pharma US Inc at 40.3% of the total. Reporting peaked in 2019 at $735 and has fallen 81.5% since, to $136 in 2025. That places this record below the midpoint for urology clinicians in WV, where the typical reported total is $2,534.
Across 112 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$939
- Sumitomo Pharma America, Inc.$170
- Pfizer$167
- AbbVie$134
- Dornier Medtech America, Inc$131
- Boston Scientific$117
- plus $673 from 20 others
What the payments were for
- Food & beverage$2,12991%
- Education$2029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 44 | $939 |
| Sumitomo Pharma America, Inc. | 10 | $170 |
| Pfizer | 11 | $167 |
| AbbVie | 6 | $134 |
| Dornier Medtech America, Inc | 1 | $131 |
| Boston Scientific | 4 | $117 |
| Neotract Inc. | 4 | $64 |
| Axonics, Inc. | 3 | $63 |
| Tolmar Pharmaceuticals, Inc. | 2 | $53 |
| Myriad Genetic Laboratories, Inc. | 3 | $52 |
| Merck | 3 | $47 |
| Progenics Pharmaceuticals, Inc. | 2 | $46 |
| Laborie Medical Technologies Corp. | 1 | $45 |
| Myovant Sciences Inc. | 3 | $44 |
| Procept Biorobotics Corporation | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Tolmar, Inc. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $22 |
| Novartis | 1 | $17 |
| Photocure Inc | 1 | $16 |
| Bayer | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Coloplast | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Urogen Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$131
How this compares
$2,330 in reported general payments places this provider in the 40th percentile of 67 urology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 92 | $71,464 |
| GemtesaVibegron | 33 | $24,129 |
| Methenamine Hippurate | 184 | $12,429 |
| Tamsulosin Hcl | 433 | $4,974 |
| Potassium Citrate ErPotassium Citrate | 48 | $3,904 |
| Solifenacin Succinate | 40 | $2,929 |
| Finasteride | 252 | $2,661 |
| Clonidine | 17 | $1,616 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 91 | $1,404 |
| Estradiol | 19 | $1,356 |
| Oxybutynin Chloride ErOxybutynin Chloride | 79 | $910 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $382 |
| Ampicillin Trihydrate | 15 | $325 |
| Bicalutamide | 17 | $310 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 42 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $939 | $71,46492 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $170 | $24,12933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 67 urology providers in West Virginia.
Other urology in Parkersburg
- Patrick DuganParkersburg$2K
- Jaschar Shakuri-RadMorgantown$77K
- Ali HajiranMorgantown$37K
- Lynnetta PayneBeckley$23K
- Stanley ZaslauHuntington$14K
- John BarnardMorgantown$10K
- Mohamad SalkiniMorgantown$8K
- Joshua LohriCharleston$8K
- Nathan HaleCharleston$7K
- Rocco MorabitoHuntington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.